Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT05068934Completed

The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF Patients

Role: lead

NCT06812546Phase 4Not Yet Recruiting

Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

Role: lead

NCT06604611Phase 4Not Yet Recruiting

Colchicine in Patients with Heart Failure with Preserved Ejection Fraction and Inflammation

Role: lead

NCT06245980Unknown

Role of SGLT2I in Patients With Myocardial Infarction

Role: lead

NCT05059769Unknown

Relationship Between Ambulatory Arterial Stiffness Index and Left Ventricular Diastolic Function in Patients With HFpEF

Role: lead

NCT03984071Completed

The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI

Role: lead

NCT03740776Completed

The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI

Role: lead

All 7 trials loaded